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Background: Tumor angiogenesis is critical for tumor growth, infiltration and metastasis. Vascular endothelial
growth factor (VEGF) is a potent angiogenic factor and targeting it is important in reducing angiogenesis.
Bevacizumab (Avastin), a monoclonal antibody that reacts directly against VEGF, has been demonstrated to be an
effective treatment for various cancers such as rectal cancer, colon carcinoma, and non-small cell lung cancer, etc.
Results: In the current study, we used the phage display technique to generate mimotopes that complemented
the screening Avastin antibody (Ab). The candidate mimotopes of VEGF were isolated from a 12-mer peptide
library. The phage displaying peptide DHTLYTPYHTHP (designated as 12P) exhibited high affinity to Avastin. The
chemically synthesized 12P was conjugated to keyhole limpet hemocyanin (KLH) by glutaraldehyde (GA) to form
vaccine KLH-12 peptide (KLH-12P). This epitope vaccine significantly induced humoral immunity in mice. The blood
serum from KLH-12P-immunized mice associated with VEGF and blocked its binding to VEGFR, thus inhibiting
vascular endothelial cell proliferation and migration.
Conclusions: Our data indicate that the isolated mimotope 12P reported here could potentially elicit specific
antibodies against VEGF and result in the induction of anti-angiogenesis responses.
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Searching for new therapies against cancer is of great
importance to human health. Recent therapeutic inter-
ventions target various aspects of cancer growth and
distant metastasis. The advancement in knowledge of
the importance of angiogenesis to tumor progression and
metastasis has driven the development of anti-angiogenic
therapies for cancer treatment. The concept of anti-
angiogenic therapy began more than 30 years ago, when
Judah Folkman demonstrated that factors released by
tumors mediate angiogenesis [1,2]. Angiogenesis is a
necessary step for tumor growth beyond 1–2 mm, as
well as for the development of metastasis [3,4].
VEGF, secreted by tumors, was first discovered in
1983 and was later shown to play a crucial role in cancer* Correspondence: Zhangw90@fmmu.edu.cn; Zhangyqh@fmmu.edu.cn
†Equal contributors
1The State Key Laboratory of Cancer Biology, Department of
Biopharmaceutics, School of Pharmacy, Fourth Military Medical University,
Xi’an, China
Full list of author information is available at the end of the article
© 2013 Li et al.; licensee BioMed Central Ltd. T
Commons Attribution License (http://creativec
reproduction in any medium, provided the orinitiation, progression and angiogenesis stimulation [5].
Since then, therapeutic agents that target VEGF have
been developed and tested. It has been shown that an
anti-VEGF antibody can reduce the blood vessel density
in a given microscopic area in a tumor, termed the
microvessel density, and inhibit the growth of some
tumors in nude mice [6]. Also, bevacizumab (Avastin),
which is a humanized monoclonal antibody that binds
VEGF, has been approved for the treatment of cancer.
However, these therapeutic antibodies have serious
practical limitations [7], including obstacles in production.
In addition, antibiotictherapy is expensive and requires
repeated administration over a long period of time.
Mimotopes are small peptides that structurally mimic
a given antibody-binding site of an epitope and can be
recognised by the immune system [8,9]. Active immu-
nization using mimotopes induces antibodies to recognize
the mimicked epitope. Becuase mimotopes can produce
ongoing immune responses [10], avoid repeated admin-
istration, provide affordable medicines, and lead to
broader patient acceptance and compliance, they mayhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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can be isolated from phage display peptide libraries [11]
and have been shown to drive active immune responses
towards the original antigen, thus leading to effective
immunity. They are usually used in the development of
vaccines against many kinds of diseases [12-15]. Li reported
that mimotopes induced the production of protective
antibodies, and consequently, became candidates for the
development of potential vaccines [16].
In this study, we investigated alternative anti-angiogenic
therapies and exploited phage display technology to
identify the peptides that can mimic the natural VEGF
epitope. The PhD.-12™ Phage display peptide library was
immunoscreened and the selected phage plaques were
analyzed. The mimotopes were used to immunize mice and
the immune responses for the phagotopes were evaluated.
Results
Biopanning and screening
A library of random 12 mer peptides was screened with
Avastin. As the first indicator of successful biopanning,
an increase of phage titers during rounds of panning was
observed. The phage titer increased from 1.21 × 108
plaque forming units (pfu)/μL (first round) to 1.02 × 109
pfu/μL (second round) and finally to 7.59 × 109 pfu/μL
(third round). A total of 80 phage plaques were randomly
chosen for colony screening after three successive rounds
of biopanning. Among them, 42 phage plaques with the
highest affinity with Avastin, but not with control or the
blocking protein (BSA), were found and amplified. All
candidates showed comparable binding intensities. The
















Figure 1 Binding specificity of selected phages from the Ph.D.-12TM P
coated with Avastin mAb, control antibodies or BSA by incubation at 4°C o
were added to the wells, allowed to bind at room temperature for 2 h and
DHTLYTPYHTHP; Phage 2: phage plaques displaying peptide NHFGKFLDALA
All assays were carried out in triplicate and the error bars indicate standardand two mimotope candidates (DHTLYTPYHTHP and
NHFGKFLDALAG) were specifically recognized by the
selecting antibody, Avastin. The DHTLYTPYHTHP insert
was the sequence most frequently found, indicating high
reactivity of the corresponding peptide with the Avastin
paratope. The NHFGKFLDALAG sequence was also
deduced from the sequencing result. The positive phage
candidates containing these two mimotopes were specific-
ally recognized by Avastin, but not by control antibodies
or BSA. Moreover, Avastin did not react with the 12-mer
peptide control phage (Figure 1).
Binding of Avastin to the peptide displayed on phages
To determine whether the peptide still has the ability to
bind to Avastin upon removal from the phage, DHTLY
TPYHTHP (designated as 12P), the most frequently found
in positive phage plaques, was chemically synthesized.
The mimotope 12P was specifically recognized by
Avastin only (Figure 2A). In addition, a dose-dependent
increase in the binding of 12P to Avastin was observed
viaELISA (Figure 2B). Further experiments revealed that
VEGF can compete with 12P to bind to Avastin (Figure 2C).
Association of mimotope conjugates with Avastin
Dot blot assay was performed to investigate the specific
recognition of the synthetic mimotope constructs by
Avastin. The antigen 12P-KLH was associated with
Avastin (lane 1), but not control peptide-KLH and
KLH (lanes 2 and 3, respectively). As shown in Figure 2D,
DHTLYTPYHTHP-KLH was the only one of the three
KLH conjugates that was specifically recognized by
Avastin.cizumab Abciximab Omalizumab
hage display peptide library. Wells of 96-well microtitre plates were
vernight and blocked with 1% BSA in TBS. Affinity-selected phage
determined at OD490. Phage 1: phage plaques displaying peptide
G; Control phage: uncombined phage in the first round of panning.
deviation.
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Figure 2 Synthesized peptide (12P) binding to Avastin. (A) ELISA of DHTLYTPYHTHP bound to Avastin, the control antibodies and BSA are
shown here. Each antibody solution was added to the wells and incubated overnight, after which the wells were blocked with 1% BSA and
C-terminally biotin-labeled 12P or control peptide was added. The plates were again washed and HRP-conjugated streptavidin was then used to
act with OPD. A representative result of three experiments is shown. (B) 12P binding to Avastin is dose-dependent. The 96-well plate was coated
with Avastin. The binding ability of 12P (filled diamond) or control (filled square) with Avastin was analyzed. A representative result of three
experiments is shown. (C) 12P binding to Avastin can be blocked by VEGF. The 96-well plate was coated with Avastin. After blocking with 1%
BSA, the plate was incubated with the indicated amount of VEGF and 800 ng 12P per well. A representative result of three experiments iss
shown. (D) Specific recognition of the synthetic mimotope constructs by Avastin (Dot Blot). Lane 1, 12P-KLH; lane 2, Control peptide-KLH; lane 3,
KLH. A representative experiment of three performed is shown.
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In this assay, 12P-KLH, control peptide-KLH and KLH
immunogenicity was evaluated in BALB/c mice. All 12P-
KLH-immunized mice developed high anti-mimotope
titers (>1:100,000), indicating successful immunization
in these mice. The pre-immune serum, serum after
immunization of 3 groups were collected and purified
for further experiment. The antiserum and purified
antibody from 12P-KLH-immunized mice recognized
the recombinant VEGF protein (Figure 3A). Furthermore,
the purified antibody from 12P-KLH immunized mice
could block VEGF binding with VEFGR (Figure 3B).
Antiserum inhibited the proliferation and migration of
human umbilical vein endothelial cells
We further assessed the effect of anti-12P-KLH anti-
bodies on the apoptosis of vascular endothelial cells.
Methyl thiazolyl tetrazolium (MTT) analysis showed
that the purified antibody from 12P-KLH immunized mice
inhibited the proliferation of HUVECs. This effect was
blocked by the 12P peptide (Figure 4A). Tube formation
was also decreased by the purified antibody from 12P-
KLH immunized mice. Consistent with the above result,
12P peptide abolished the inhibition of tube formation
effect of anti-12P-KLH (Figure 4B). Migration assay results
showed that the migrated cells were 297 ± 22.7 (Anti-
KLH), 288 ± 24.5 (Anti-Control-KLH), 153 ± 19.3 (Anti-
12P-KLH), 266 ± 31.6 (Anti-12P-KLH± 12P) and 72 ±
18.9 (Avastin), respectively (Figure 4C,D). The mobility of
the HUVECs was significantly lower in the anti-12P-KLH
and Avastin groups compared to the other three groups.
Discussion
The phage-displayed technique is a useful tool in selecting
small peptides that mimic antigens. Peptide mimotopes
can bind to antibodies which are raised against native
structures. The strategy of using obtained peptide mimics
(mimotopes) as low molecular weight substitutes of the
natural antigen for active immunization could potentially
elicit specific antibodies and result in the induction of
long-lasting humoral immune responses. In the case of
mimotope immunization, several studies have shown
effective responses in vivo [17]. Importantly, the mimotopes
are able to replace the original epitopes for vaccinedevelopment [18,19]. Furthermore, active immune responses
induced by phage-displayed mimotopes have been verified
in many diseases [20-22]. Mimotopes can potentially serve
as lead compounds in the development of low molecular
weight substitutes of the template protein for use in
drug and vaccine design [23]. This may be an effective
strategy to overcome the serious practical limitations of
the therapeutic monoclonal antibodies, e.g. Avastin.
In this study, a library of random 12 mer peptides
was used to identify the VEGF epitope (mimotope)
using Avastin as a selector molecule. After three rounds
of biopanning, two amino acid sequences were deduced
from these phage plaques. We isolated two peptide
mimics (DHTLYTPYHTHP and NHFGKFLDALAG) of
the epitope that were specifically recognized by the
Avastin mAb. We aligned the mimotope sequences and
did not observe any homology between the two mimotopes
and the known amino acid sequence of VEGF. Many
researchers have demonstrated similar results to ours.
One reason for the disparity between the two mimotopes
and VEGF might be that the epitopes that are recognized
by Avastin could be a discontinuous amino acid sequence
due to the folding of peptides, thus forming a conform-
ational epitope [19]. MimoPro is a new graph-based map-
ping method for epitope prediction using affinity-selected
peptides derived from phage display experiments and is
freely accessible through the MimoPro server [24]. We
used MimoPro to analyze the two newly isolated peptide
mimics, as well as mimotope M074_D12 [25]. As
shown in Additional file 1: Figure S1, the mimotope
12P (DHTLYTPYHTHP) had the highest score among
the three, suggesting that 12P shares the most similar
structure with VEGF.
To demonstrate the affinity between the insert sequences
displayed on positive phage plaques and Avastin, the
results of colony screening were confirmed by ELISA.
12P was specifically recognized by the selecting antibody
Avastin, but not by the control antibody or BSA. In
addition, the binding of 12P to Avastin was observed in
a dose-dependent manner. Most importantly, VEGF
could compete with 12P in binding to Avastin.
Due to immune tolerance, the use of a natural epitope
peptide alone is insufficient for inducing an immune





































Figure 3 The immunized mouse serum antibody recognizing VEGF and blocking VEGF binding with VEFGR. (A) Wells of 96-well microtitre
plates were coated with the recombinant VEGF (50 ng/well) and, after blocking, were incubated with the mouse serum: 4% pre-immune serum; 4%
serum after immunization or 2 μg/ml purified antibody of immunized mice serum. The antiserum elicited by 12P-KLH could bind to VEGF. This result is
representative of three independent experiments. (B) Wells of 96-well microtitre plates were coated with the recombinant VEGFR2 (10 ng/well) and
then incubated with VEGF with or without purified serum. Bound human VEGF was detected with a rabbit anti-human VEGF and following anti-rabbit
IgG conjugated with HRP. All assays were carried out in triplicate and the error bars indicate standard deviation. Statistical analysis was performed using
the Student’s t test (*p < 0.05).
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proteins were then applied for Dot blot analysis. We
found that 12P-KLH was associated with Avastin, butnot control-KLH or KLH. This indicated that 12P-KLH
was the only conjugate vaccine of the three peptides














































Figure 4 Antiserum from 12P-KLH-vaccinated mice inhibited proliferation, matrigel tube formation and migration of HUVECs. (A) MTT
assay of vascular endothelial cells treated with the indicated groups: anti-KLH, anti-control-KLH, anti-12P-KLH. 12P was used to block the function
of anti-12P-KLH and Avastin was used as the positive control. All assays were carried out in triplicate and the error bars indicate standard
deviation. Statistical analysis was performed using the Student’s t-test (*p < 0.05). (B) Inhibition of tube formation of HUVECs treated with
antibodies was detected on Matrigel. HUVECs (1 × 105/ml) were seeded on top of the matrigel with complete RPMI 1640 medium containing
antibodies and cultured for 8 h. The representative photographs were taken using a light microscope (200× view field). (C) HUVECs were seeded
in the upper chamber of a Millicell insert with RPMI 1640 containing antibodies and incubated with 10% FCS RPMI 1640 medium containing
5 ng/ml VEGF in the lower chamber for 12 h. The cells were fixed and stained with 4,6-diamidino-2-phenylindole (DAPI). The migrated cells were
visualized under a microscope. A representative image of DAPI staining is shown. (D) Data of C was analyzed by Student’s t-test. *p < 0.05. All of
the assays were carried out in triplicate and the error bars indicate standard deviation.
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immunogenicity of the conjugations. Mice immunized
with KLH and control-KLH only developed antibodies
against KLH but not VEGF. All mice immunized with
12P-KLH successfully developed high titers of antibodies
against VEGF as well as the KLH, indicating successful
immunization in mice.
It was crucial to determine whether the anti-12P-KLH
antibodies could bind to the VEGF protein. Therefore,
we performed experiments to demonstrate whether the
immunized serum was specific for VEGF. Our results
demonstrated that the conjugated vaccine containing 12P
mimicked the natural VEGF epitope and was capable of
inducing an active, specific antibody response to VEGF.
Altogether, our findings showed that the phage-displayed
epitope was able to mimic immunological properties of
the native epitope on VEGF. Furthermore, using 12P-KLH
as the antigen, we were able to detect the antibody in
the serum from immunized animals and the latter could
block VEGF binding to VEGFR2.
Without new blood vessels and a functional vasculature,
tumors are limited in their ability to grow and tumor cell
proliferation would give way to apoptosis. The purpose of
our study was to generate mimotope vaccines that could
induce the generation of antibodies against VEGF. We
further assessed the effect of purified anti-12P-KLH
antibodies on the vascular endothelial cells (HUVECs).
Decreased proliferation of HUVECs after treatment
with anti-12P-KLH antibodies was observed, compared
with equal amounts of anti-control-KLH or anti-KLH
antibodies. Tube formation and cell migration were also
decreased by anti-12P-KLH antibodies. The anti-12P-KLH
antibody-induced effects were abolished by the 12P
peptide. Our findings showed that the anti-12P-KLH
antibodies could remarkably block the tube formation,
proliferation and migration induced by VEGF on HUVECs.
The strategy of generating 12P-KLH vaccine constructs
for active immunization has many advantages. For example,
the mimotopes are easily synthesized and conjugated,
and can actively induce continuously available antibodies
against VEGF. Our results suggest that the phagotope
12P provides a convenient and economic approach to
preparing antigens, and could be used in anti-angiogenic
therapy.
Conclusions
The commercialized antibody, Avastin, is a promising
anti-tumor agent that recognizes VEGF and suppresses
angiogenesis. To overcome its limitations, we generated
epitope mimics that bind to Avastin and tested whether
the peptide mimics could induce the production of similar
antibodies upon active immunization of mice with the
peptides. We used the Ph.D-12 phage display peptide
library to identify peptides that bind to Avastin. Twomimotopes (DHTLYTPYHTHP and NHFGKFLDALAG)
were shown to bind to the mAb. The most frequently
selected mimotope, DHTLYTPYHTHP (12P), was conju-
gated to KLH and used to immunize BALB/c mice. Anti-
serum from 12P-KLH-immunized mice could recognize
the recombinant VEGF, whereas sera from mice immu-
nized with the control peptide-KLH or carrier KLH alone
failed to show similar reactivity. Furthermore, anti-12P-
KLH antibodies induced the inhibition of tube formation,
proliferation and migration of HUVECs. Our data indicate
that the isolated mimotope 12P reported here could po-
tentially elicit specific antibodies against VEGF and result
in the inhibition of human umbilical vein endothelial cells.
Methods
Cell lines, animals and monoclonal Abs
The human umbilical vein endothelial cells (HUVECs),
purchased from Shanghai Institutes for Biology Sciences
of the Chinese Academy of Sciences, were routinely
cultured in monolayers at 37°C with 5% CO2. Cells were
maintained in RPMI 1640 medium (Gibco, USA) supple-
mented with 10% heat-inactivated fetal bovine serum,
100 μg/ml ampicillin and 100 μg/mL streptomycin. Seven-
week-old healthy female BALB/c mice, purchased from the
National Rodent Laboratory Animal Resource (Shanghai,
China), were cared for under institutional animal care
protocols. Bevacizumab (Avastin) was purchased from
Roche (Switzerland). Abciximab (ReoPro) and Omalizumab
(Xolair) were purchased from Eli Lilly (Switzerland).
Isotype-matched human IgG1 Fc control was purchased
from R&D (USA). Both rhVEGFA and rhuman VEGFR
were purchased from Sino Biological Inc. (Beijing, China).
Anti-human VEGF was obtained from ABcam (England).
Phage library and biopanning
A total of three successive rounds of panning with Avastin
were performed with a random phage display 12-mer
peptide library (BioLabs, New England) that expressed
random 12-mer peptides at the N-terminus of the
minor M13 phage coat protein. The procedure for
screening the phage display library was performed
according to instruction of the manufacturer of the kit.
Briefly, 96-well ELISA plates were coated with 20 μg/
well of Avastin overnight at 4°C. Wells were blocked
for 2 h with 1% bovine serum albumin (BSA) (Sigma,
USA) in TBS and incubated with an aliquot of the
phage library (2 × 1011 phage particles) in binding buffer
(TBS, 0.1% Tween-20 or 0.5% Tween-20). Unbound phage
particles were removed by extensive washing with TBS/
0.5% Tween 20. Bound phages were eluted with 0.2 M
Glycine–HCL/0.1% BSA, pH 2.2 and immediately neutral-
ized. Phages were amplified in Escherichia coli ER2738,
precipitated from the bacterial culture supernatant with
polyethylene glycol, and then titered before the next round
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elution or amplification phases were plated in serial
dilutions on Luria broth agar plates containing 20 μg/
mL of tetracycline.
Phage plaques screening assay
After three rounds of biopanning, screenings for the
selection of specific phage plaques were completed.
Immunoscreenings were performed with Avastin and
control. Wells were coated with Avastin (100 ng/well)
overnight at 4°C. After blocking, phage plaques (1 ×
109/well) were added to the wells and incubated for
2 h at room temperature. Wells were washed 10 times
with TBS/0.5% Tween 20 and bound phage was
detected by HRP-conjugated anti-M13 monoclonal anti-
body (Amersham Biosciences, Germany). The reaction
was developed with OPD (Sigma, USA). The absorption
value was measured at 490 nm with a Bio-Rad ELISA
reader. Positive phage plaques were amplified and identified
by DNA sequencing.
Specificity enzyme-linked immunosorbent assay
ELISA plates were incubated with Avastin or control
antibodies (100 ng/well) overnight at 4°C. Plates were
then washed with PBS containing 0.1% Tween 20 and
blocked with PBS containing 0.1% Tween 20 and 1%
BSA prior to the addition of phage particles. Bound
phage particles were detected using an HRP-conjugated
anti-M13 monoclonal antibody. The reaction was devel-
oped with ABTS as the substrate and measured with a
Bio-Rad ELISA reader (OD490).
DNA sequencing
Single strand phage DNA was prepared with 20% poly-
ethylene glycol-8000 (PEG)/NaCl according to the ran-
dom phage display 12-mer peptide library kit. Prepared
DNA amounts were verified by EtBr2/0.8% agarose gel
under UV illumination. DNA sequencing was done by
Sangon (ShangHai, China).
Peptide synthesizing
The selected peptides (DHTLYTPYHTHP (designated as
12P) and corresponding scrambled control peptide PHY
TPTYTDHHL (designated as control)) were synthesized
(HuaChen, China). Peptide concentrations were calculated
based on OD280. The chemically synthesized 12P was
conjugated to keyhole limpet hemocyanin (KLH) by
GA to form the KLH-12 peptide (KLH-12P). Conjugation
procedures were as follows: the peptide was mixed with
the carrier protein solution in PBS (1 mg/ml, pH 7.4) at
a peptide to KLH ratio of 40:1. The same volume of GA
solution was added drop-by-drop to the stirring peptide/
protein mixture, which was then incubated at 4°C for 1 h.Uncoupled peptides were removed by size exclusion chro-
matography, using Sephadex G-25 (Pharmacia, USA).
Dot blot assay
Avastin was used in a dot blot assay to measure conjugate
binding capacity. The conjugate vaccine protein (1 μg)
was dotted onto a nitrocellulose membrane. Blot strips
were then incubated with Avastin (1 μg) or control Ab.
Bound Abs were detected with an alkaline phosphatase-
conjugated secondary antibody and western blue as the
substrate (Promega, USA).
VEGF competing assay
The 96-well plate was coated with aliquots (100 μl) of
Avastin at 4°C overnight. After blocking with 1% BSA at
37°C for 2 h, the plates were washed three times with
PBST. The plate was then incubated with 0, 100, 200,
400 or 800 ng of VEGF and 800 ng biotin-labeled 12P
per well at room temperature for 1 h. The plates were
washed again and HRP-conjugated streptavidin was then
used to act with OPD.
Immunization of BALB/c mice
Four groups (n = 6 per group) of BALB/c mice were im-
munized by repeated subcutaneous injections of50 μg of
DHTLYTPYHTHP-KLH, control peptide-KLH, KLH alone,
or physiological saline on days 1, 15 and 29. Mice were
boosted (i.p.) on day 43 and sacrificed on day 53 for
serum analysis. The complete Freund adjuvant/incomplete
Freund adjuvant (CFA/IFA) (SIGMA, USA) was used as
an adjuvant in all groups.
Antiserum titer determination
Titers of sera from the immunized BALB/c mice against
VEGF (Sigma, USA) were determined via ELISA. The
96-well plates were incubated with 50 ng VEGF/per well
in 0.1 M NaHCO3 overnight at 4°C, pH 8.6. Wells were
blocked with 1% BSA in PBS (pH 7.4, 2 h, 4°C). After
washing the bound antigen with PBS–0.3% Tween 20,
antiserum was added to the wells and incubated for 1 h
at 37°C, followed by washing and incubation with the
second antibody. The color was developed using ABTS
(Sigma, USA) as the substrate. The absorbance was mea-
sured at 490 nm.
Antibody purification
Total serum was collected at day 53 for purification.
Ammonium sulphate was added to serum (50% saturated).
Precipitates were separated by centrifugation, dissolved in
PBS buffer and dialyzed overnight to remove ammonium
sulphate. Then DEAE chromatography (GE, Sweden) was
applied and eluted fractions related to diagram’s peak were
collected and after precipitation with ammonium sulphate
were used for G-50 Sephadex gel filtration chromatography
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of 10 ml per hr and optical absorption was read at 280 nm.
Functional assays of antiserum
Matrigel (Collaborative Biomedical, Bedford, MA) was
added (250 μL) to each well of a 24-well plate and was
left to polymerize at 37°C for 1 h. HUVECs were seeded
onto the plate at a density of 50,000 cells per well and
treated with the antiserum dilution at 37°C for 8 h. For
the proliferation assay, HUVECs were seeded onto the
plate and cultured as monolayers at 37°C in conditioned
RPMI 1640 media supplemented with 5 ng/ml of VEGF.
After reaching 80% confluence, antibodies purified from
the antisera were added and the plates were incubated
for 72 h. Then MTT assay was used to assess cell activity.
For the migration assay, HUVECs were seeded onto the
upper wells of a Millicell Insert in conditioned medium
containing antibodies purified from antisera and incubated
for 24 h at 37°C. Avastin was used as the positive control.
Cell migration was measured by counting the number of
migrated cells in five random non-overlapped fields at
100× magnification.
Statistical analysis
Data were analyzed by Student’s t test. Results were
expressed as the means ± standard deviations (SD). A p
(probability) value < 0.05 was considered to be significant.
Additional file
Additional file 1: Figure S1. 3D images of the results from MimoPro.
The patch with the highest score is selected as a potential candidate for
the native epitope. (A) In section “Candidate Epitope”, all potential amino
acids are listed and each amino acid is printed in the format of [Single
letter identifier] [No. in chain]. In the section “Alignment for each
mimotope”, the resultant alignments for individual peptide sequences are
tabulated. 3D analysis (B) 12P, (C) NHFGKFLDALAG and (D) M074_D12 are
shown. The candidate epitopes of 1VGH are shown in the shape of
spacefill and cpk color format with the rest amino acids in backbone.
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